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Abstract
Background: The oncogene PTI-1 was originally isolated from a prostate cancer cell line by its capability to
transform rat fibroblasts. The PTI-1 mRNA has a very eccentric structure as the 5′UTR is similar to prokaryotic 23S
rRNA, while the major open reading frame and the 3′UTR corresponds to a part of the mRNA encoding human
translation elongation factor eEF1A1. Thus, the largest open reading frame encodes a truncated version of eEF1A1
lacking the first 67 amino acids, while having three unique N-terminal amino acids. Previously, the UTRs were shown
to be a prerequisite for the transforming capacity of the PTI-1 transcript. In this study, we have investigated the
possible role of the UTRs in regulating protein expression and localization.
Methods: The protein expression profiles of a number of PTI-1 mRNA variants were studied in vitro and in vivo.
Furthermore, the oncogenic potentials of the same PTI-1 mRNAs were determined by monitoring the capacities of
stably transfected cells expressing these mRNAs to induce tumors in nude mice and form foci in cell culture. Finally,
the cellular localizations of PTI-1 proteins expressed from these mRNAs were determined by fluorescence microscopy.
Results: The PTI-1 mRNA was found to give rise to multiple protein products that potentially originate from translation
initiation at downstream, inframe AUGs within the major open reading frame. At least one of the truncated protein
variants was also found to be oncogenic. However, the UTRs did not appear to influence the amount and identities of
these truncated protein products. In contrast, our localization studies showed that the UTRs of the transcript promote a
nuclear localization of the encoded protein(s).
Conclusions: Translation of the PTI-1 mRNA results in multiple protein products of which (a) truncated variant(s) may
play a predominant role during cellular transformation. The PTI-1 UTRs did not seem to play a role in translation
regulation, but appeared to contribute to a nuclear localization of the PTI-1 protein(s). This indicates that the PTI-1
protein(s) exert(s) its/their oncogenic function inside the nucleus.
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Background
Prostate tumour inducing gene 1 (PTI-1) encodes a vari-
ant of eukaryotic elongation factor 1A1 (eEF1A1). The
canonical role of eEF1A is to deliver aminoacylated-
tRNA to the mRNA-programmed ribosome during
translation. In addition, a number of alternative func-
tions in e.g. cytoskeletal organization and signaling
pathways have been reported [1].
The composition of the PTI-1 mRNA (Figure 1) is
unusual as its 5′UTR (620 bp) is homologous to 23S ribo-
somal RNA from Mycoplasma, while the 3′UTR (289 bp)
is a truncation of the eEF1A1 3′UTR [2]. The major open
reading frame (ORF1; 1197 bp) encodes a truncated
version of eEF1A1 lacking the first 67 amino acids, while
presenting three unique N-terminal amino acids. Other-
wise, the sequences of the PTI-1 and eEF1A1 proteins are
identical [3].
The exact identity of the protein encoded by the PTI-1
mRNA is uncertain despite of the obvious coding po-
tential of ORF1. The start codon flanking ORF1 is
found in a suboptimal Kozak context lacking the G+4.
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Furthermore, it is preceded by nine ATG codons in the
5′UTR (Figure 1). This makes high-level expression of
the full-length PTI-1 protein unlikely as previously
confirmed [3] and opens the possibility that truncated
protein products encoded by the mRNA might also be
of possible importance during cellular transformation.
PTI-1 was initially discovered in a prostate cancer cell
line, LNCaP, during a screen for new oncogenes [4]. The
oncogenic phenotype of the isolated PTI-1 was confirmed
by its ability of rendering stably transfected CREF-Trans 6
cells tumorigenic. Later, downregulation of PTI-1 mRNA
levels was shown to reduce growth and induce apoptosis
in two other prostate cancer cell lines DU145 and PC3 [5].
The mechanism by which the PTI-1 gene exerts its onco-
genicity is unknown. It has previously been speculated that
the oncogenic properties of the PTI-1 protein might result
from interference with one or more of the functions of the
strongly related eEF1A [6]. Notably, the mammalian iso-
form of eEF1A specific to brain, heart and muscle cells,
eEF1A2, has been shown to be able to transform mamma-
lian cells and to be overexpressed in a number of tumour
tissues from e.g. ovary, breast and lung [7].
Remarkably, previous studies demonstrated that only
the full-length PTI-1 mRNA is oncogenic, while expres-
sion of neither the 5′UTR alone, ORF1 alone, nor the
5′UTR and ORF1 expressed together as separate con-
structs caused the cells to be tumorigenic [8]. However,
the explanation for the essential role played by the PTI-
1 UTR regions in transformation remained unknown.
The UTR regions may contain various cis-acting regula-
tory sequence elements with an impact on mRNA sta-
bility, localization and translation [9]. Genes associated
with cell proliferation such as oncogenes and tumour sup-
pressor genes tend to present atypically long and complex
5′UTRs that often contain these regulatory elements [10].
In addition, upstream ORFs have been demonstrated to
have regulatory potential [11].
In this study, the potential role of the UTRs of the PTI-
1 mRNA in regulating translation and protein localization
has been investigated in order to understand the essential




The protein expression profile of full-length PTI-1 mRNA
(PTI-1-FL) was initially analyzed using an in vitro tran-
scription/translation kit. The resulting products were ana-
lysed on two types of gels to allow a clear separation of
bands in the area from 25–50 kDa (Figure 2A) and to re-
veal potential products smaller than 25 kDa (Figure 2B).
Several protein products resulted from both the positive
Xenopus eEF1A control (Figure 2A and B, lane 1) and the
full-length PTI-1 template (Figure 2A and B, lane 3). No
bands were observed for the negative control without
DNA (Figure 2A and B, lane 2). The presence of mul-
tiple bands could be due to degradation of mRNA/pro-
tein and/or it could be due to translation initiation
occurring from multiple AUG codons. No ORFs unre-
lated to ORF1 (Figure 1) exist in the PTI-1-FL mRNA
that could give rise to bands of the observed sizes. How-
ever, a number of down-stream, in-frame AUGs exists
within ORF1 that could potentially give rise to bands of
the observed sizes (marked by bold, vertical lines in
Figure 1).
The upper band in the Xenopus eEF1A contol corre-
sponds to a protein product of approximately 50 kDa as
expected upon initiation from the canonical start codon.
Right below the upper band, a faint band is observed,
which might represent a protein product of approx.
45 kDa initiated at the second, in-frame AUG codon
(marked by an asterisk in Figure 2A). The third band po-
tentially represents a 39-kDa protein product initiated at
the third in-frame AUG codon in the Xenopus eEF1A
Figure 1 Schematic overview of the PTI-1 mRNA. The parts with similarity to 23S rRNA and eEF1A1 mRNA are indicated. Upstream AUGs are
marked with thin, vertical lines, while the AUG initiating the longest ORF, ORF1, as well as the first three downstream, inframe AUGs are marked
with bold, vertical lines. The first positions of the ORF start codons are numbered according to the full-length PTI-1 mRNA (NCBI accession number
L41498). The corresponding ORFs are indicated as grey arrows and the calculated molecular weights resulting upon translation of these ORFs are
provided to the right of the arrows. The AUG subject to mutation in the different PTI-1-FL-ΔATG constructs is marked with an asterisk.
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template. This band is shared by the PTI-1-FL template
(Figure 2A, lane 3) and could represent a protein pro-
duct corresponding to ORF2 of the PTI-1-FL template
(Figure 1). Above the common band of 39 kDa, a pro-
duct of approximately 43 kDa is observed for the PTI-1-
FL template, which fit with the size expected upon
translation from ORF1. The two bands migrating faster
than the 39 kDa band observed for both the Xenopus
eEF1A and the PTI-1-FL template, could potentially re-
present protein products of 33 and 28 kDa originating
from translation initiations from successive downstream,
in-frame AUGs, which are all conserved between the
two sequences (corresponding to ORF3 and ORF4 of the
PTI-1 mRNA, Figure 1). No proteins of lower molecular
weight could be clearly distinguished (Figure 2B).
The intensities of products potentially resulting from
initiations at downstream AUGs in the full-length PTI-1
mRNA were similar to that of the largest product indi-
cating a possible role of these smaller proteins in cellular
transformation. Remarkably, the expression that is likely
to originate from ORF2 appeared to be higher than that
observed from ORF1 (Figure 2, lane 3).
In vitro transcription/translation systems are known to
give rise to internal initiation of translation that does not
take place in vivo [12,13]. This inherent flaw of the sy-
stem might give rise to protein products whose transla-
tion in vivo would be hindered by the 5′UTR of the
PTI-1 mRNA. Thus, in vivo analysis of transient protein
expression from constructs containing the sequence en-
coding a V5-tag situated immediately before the stop
codon flanking ORF1 was conducted. This allowed the
detection of full-length protein products as well as pro-
ducts initiated from downstream, inframe AUGs. In this
analysis, two additional constructs were included: a con-
struct giving rise to an mRNA containing only ORF1
without UTRs (pcDNA3.1-PTI-1-ORF1-V5) and a full-
length construct with a mutation of the startcodon of
ORF1 (pcDNA3.1-PTI-1-FL-ΔATG-V5). The first con-
struct allowed an evaluation of the possible regulatory
effect of the 5′UTR on translation, while the second
construct was included to substantiate our theory that
downstream in-frame AUGs might be recognized during
translation initiation. The sizes of the proteins expressed
in vivo in transfected NIH 3 T3 cells (Figure 3) were
very similar to those of the products observed in vitro
(Figure 2). Again, four specific protein products could
be detected, likely representing initiation from each of
the first four in-frame AUGs in ORF1. No translation
products could be detected for any of the succeeding,
potential downstream ORFs. Notably, the upper band
obtained from the pcDNA3.1-PTI-1-FL-ΔATG-V5 con-
struct (Figure 3, lane 3) migrated to the same position as
the second band in lanes 1 and 2 indicating that the
latter bands most likely stem from translation of ORF2
(Figure 1). Remarkably, the products obtained using the
ORF1-only template and the full-length template were
the same i.e. the 5′UTR did not appear to change the
identity of the proteins expressed, but the intensities of
the two upper bands (ORF1 and ORF2) were markedly
reduced in the cells transfected with pcDNA3.1-PTI-1-
FL-V5. In general, initiation from downstream AUGs
seemed reduced in vivo. However, potential expression
Figure 2 In vitro transcription/translation of protein from the PTI-1 gene. Protein products are visualized by gel electrophoresis followed by
autoradiography. A. Analysis on a 12% polyacrylamide gel. B. Analysis on a precast 12% BIS TRIS gel run in MES buffer. Lanes 1: positive control
encoding Xenopus eEF1A; Lanes 2: negative control without DNA template; Lanes 3: transcription/translation from the pZeoSV2-PTI-1-FL construct.
Arrows indicate the bands with potential correspondance to protein products resulting upon translation of ORFs 1, 2, 3 and 4 shown in Figure 1.
The weak band in lane 1 marked by an asterisk may correspond to the product resulting upon translation from the second in-frame AUG of the
Xenopus eEF1A template.
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from ORF2 still appeared reasonably high and might
give rise to a protein of relevance as an oncoprotein.
Oncogenicity assays
The multiple potential expression products observed
upon expression in vitro (Figure 2) and in vivo (Figure 3)
indicated that the pattern of expression from the PTI-1
gene was more complex than previously anticipated.
Thus, we found it important to evaluate the transform-
ing potential of protein products resulting upon transla-
tion from downstream, inframe AUGs.
The oncogenic potentials of variants of the PTI-1 gene
were analyzed using the constructs pZeoSV2-PTI-1-
ORF1, pZeoSV2-PTI-1-FL and pZeoSV2-PTI-1-FL-ΔATG
expressing PTI-1 mRNAs comprising ORF1 only, the full-
length mRNA or the full-length mRNA with a point-
mutation in the start codon of ORF1, respectively. The
constructs were stably transfected into NIH 3 T3 cells and
analysed for their ability to induce tumor formation in
nude mice and/or to form foci in culture. Cells stably
transfected with an empty pZeoSV2 vector were used as a
negative control. Four sets of stable cell lines were estab-
lished and analyzed independently. The first and second
sets of stable cell lines were evaluated for their abilities to
induce tumors in nude mice, while the foci-forming cap-
acities of the second, third and fouth sets were determined
i.e. the transforming potential of the second set of stable
cell lines was analyzed using two different approaches.
Expression of the integrated constructs was confirmed by
RT-PCR (data not shown). The cells were tested free
of Mycoplasma contamination (data not shown). Each
36-mm well was estimated to give rise to approximately
500 individually transfected clones. No clonal isolation
was performed, and the oncogenicity assays were con-
ducted on pools of clones.
The abilities of the stably transfected cell lines to induce
tumours in nude mice upon subcutaneous injection were
tested with the first two sets of independently established
cell lines. The first set of cell lines was injected in qua-
druple (data not shown), whereafter the experiment was
repeated on a larger scale for the second set of cell lines.
Similar results were obtained in the two sets of experi-
ments. For the second set of transfections, 20 injections
were made into immunodeficient NCr nude mice for each
stable cell line. 35 days after injection, the mice injected
with the PTI-1-FL-ΔATG-transfected cells displayed 18
visible tumours. Amongst the other mice, a total of only
six small tumours were observed. The PTI-1-FL-ΔATG-
expressing cell line clearly gave rise to more and larger
tumours than any of the other cell lines (Figure 4).
All of the cell lines established during the second, third
and fourth sets of stable transfections were tested for their
foci forming potential in vitro. The experiments were con-
ducted in cells that had been propagated at subconfluency
for 12 days after ended zeocin selection. Subsequently, the
cells were seeded subconfluently and incubated for three
weeks in the presence of 5% serum, whereupon foci were
scored (Figure 5). In correspondance with the mouse
experiments (Figure 4), the transforming capacity of the
PTI-1-FL-ΔATG expressing cell line was statistically sig-
nificant (Student's t-test, P < 0.03 upon comparison with
the number of foci obtained with the empty vector).
Protein localisation
As the 5′UTR seemed to be of only minor importance for
the PTI-1 protein expression pattern, the effect of this
mRNA region on protein localization was investigated.
Transiently expressed PTI-1 protein was fluorescently
stained via a C-terminal V5-tag. During transfections,
the amount of DNA was kept relatively low to avoid po-
tential overload of the internal translocation systems as
well as passive diffusion of protein via nuclear pores.
CLSM (Figure 6A) revealed that PTI-1 expressed from
pcDNA3.1-PTI-1-ORF1-V5 containing no UTR regions
Figure 3 Transient expression of V5-tagged PTI-1 in vivo. NIH 3
T3 cells were transiently transfected with the following constructs:
pcDNA3.1-PTI-1-ORF1-V5 (lane 1), pcDNA3.1-PTI-1-FL-V5 (lane 2),
pcDNA3.1-PTI-1-FL-ΔATG-V5 (lane 3) or an empty pcDNA3.1 vector
(lane 4). Cells were harvested and lysed approximately 48 hours post
transfection. 40 μg of total protein lysate was loaded in all lanes.
Expression was analyzed by Western blotting using an anti-V5-antibody.
The presence of the V5 tag increases the molecular weight of the
expression product by 2.6 kDa. Arrows indicate the bands with potential
correspondance to protein products resulting upon translation
of ORFs 1, 2, 3 and 4 shown in Figure 1. A background band of
unknown origin appears above the ORF3 band in all lanes and
serves as a loading control.
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was primarily localized in the cytoplasm, whereas PTI-1
expressed from cells tranfected with full-length constructs,
pcDNA3.1-PTI-1-FL-V5 or pcDNA3.1-PTI-1-FL-ΔATG-
V5, was found mainly in the nucleus. For statistical pur-
poses, the assay was repeated three times and the cells
were counted in a fluorescence microscope and scored in
three catagories: mainly nuclear localization, mainly cyto-
plasmic localization or even distribution between the two
compartments. Over 100 cells were counted for each con-
struct. The result (Figure 6B) confirms the observations
made during confocal microscopy and strongly suggests
that the UTRs of the PTI-1 mRNAs examined are critical
for the nuclear localization of the corresponding PTI-1
protein.
Discussion
Protein expression from the full-length PTI-1 transcript
The nature of the protein(s) encoded by the PTI-1 gene
is so far unknown. The detection of the largest possible
protein that can result after translation of the PTI-1
mRNA (corresponding to ORF1) has been attempted
using eEF1A-specific antibodies. The results appear con-
troversial, but may depend on cell type [3,5,14]. A theor-
etical study suggests the expression of a relaxin homolog
from an uORF with potential influence on prostate can-
cer progression [15]. However, no experimental studies
have so far addressed the possible expression of trun-
cated proteins from the PTI-1 mRNA. Thus, the nature
of the protein encoded by the PTI-1 gene has stayed
uncertain.
In this study, the expression profile of the PTI-1 gene
was therefore analyzed in vitro and in vivo to determine
the size(s) of any protein(s) expressed from the full-length
gene. The result of the in vitro analysis indicated the exist-
ence of a complex pattern of translation initiation from
downstream, inframe AUG codons (Figure 2).
A similar expression pattern has been observed by
others (Figure 4 in [2]). However, these authors ascribed
the protein products of lower molecular weight to mRNA/
protein degradation or artificial initiation at down-stream
AUGs, and thus considered these proteins unimportant.
Yet, our subsequent examination of the expression profile
of the full-length transcript in vivo substantiated the inter-
pretation of different, faster migrating protein products as
the results of translation of downstream, in-frame ORFs as
the exact same expression pattern was observed (compare
Figures 2 and 3). Importantly, the largest protein pro-
duct resulting after translation of the PTI-1-FL-ΔATG
construct migrated to the same position as the second
band observed upon expression from the correspon-
ding, unmutated construct indicating that this band
may indeed be the result of translation of ORF2. Thus,
the original assignment of the first ATG in ORF1 as the
start codon of the onco-protein may be an oversimplifi-
cation [2]. It is just as likely that one or more of the
shorter products may represent the oncogenic factor(s).
This notion is emphasized by the observed transforming
capacity of the PTI-1-FL-ΔATG construct (Figures 4
and 5). Notably, removal of the start codon flanking
ORF1 by site-directed mutagenesis increased translation
from ORF2 (Figure 3) correlating with a potential role
for this eEF1A1 truncation in the transforming capacity
of the PTI-1-FL-ΔATG construct.
Similar qualitative expression patterns of eEF1A1 trun-
cations were observed in NIH 3 T3 cells transfected with
the PTI-1-ORF1, PTI-1-FL and PTI-1-FL-ΔATG con-
structs (with the absence of the uppermost band in the ly-
sates of the PTI-1-FL-ΔATG transfected cells) (Figure 3).
No protein product seemed expressed in higher amount
from the PTI-1-FL construct as compared to the PTI-1-
ORF1 construct. This demonstrates that the 5′UTR does
not cause an altered expression pattern with a higher level
of an oncogenic variant. The explanation for the require-
ment of the UTRs for the oncogenicity of the PTI-1 gene
should therefore be sought elsewhere.
The expression of a small peptide (approx. 4.6 kDa)
from a uORF as suggested in a computational analysis of
the expression potential of the PTI-1 mRNA [15] could
not be confirmed in vitro (Figure 2B), but cannot be
excluded to occur in vivo.
The oncogenic potential of the PTI-1 gene
The oncogenic potential of the PTI-1 gene was assessed via
the generation and analysis of stable cell lines expressing
Figure 4 Tumour development 35 days after injection of nude
mice with NIH 3 T3 cells stably transfected with pZeoSV2
constructs expressing variants of the PTI-1 mRNA. Each tumour
is represented as a cross. A total of 20 injections were made for each
construct. The number of tumours arisen after injection with cells
expressing the various constructs were as follows: pZeoSV2-PTI-1-ORF1:
0, pZeoSV2-PTI-1-FL: 1; pZeoSV2-PTI-1-FL-ΔATG: 18 and empty pZeoSV2
vector: 4.
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different variants of the PTI-1 mRNA. Each cell line was
established independently four times in order to rule out
the risk that observed, tumorigenic effects were caused by
a single clone with construct-independent, malign charac-
teristics. A similar pattern of oncogenic potentials was ob-
served for each set of cell lines.
As expected, PTI-1-ORF1 expression did not give rise
to tumors or significant levels of foci [8]. The anticipated
transforming property of the PTI-1-FL construct [8] was
not convincingly demonstrated under the conditions ap-
plied in this study in accordance with the previously re-
ported inefficiency of NIH 3 T3 cells as reporters of this
activity [4]. In contrast, the PTI-1-FL-ΔATG expressing
cell line gave rise to multiple tumours and foci and may
be a stronger oncogenic construct than PTI-1-FL. This
indicates that the responsible oncoprotein is encoded by
an ORF, which is shorter than the originally anticipated
ORF1 [2]. Assuming this was the case, removal of the
start codon initiating ORF1 would facilitate translation
initiation at downstream AUG codons and give rise to
increased levels of the oncoprotein, which might thereby
pass the threshold required for transformation to occur
(Figure 3; compare the intensities of the potential ORF2
products in lanes 2 and 3). The construct devoid of the
UTR regions expresses a similar amount of ORF2 pro-
duct (Figure 3, lanes 1 and 3 display the same intensities
of the potential ORF2 product) without being trans-
forming. Thus, our oncogenicity experiments support
previous experiments showing that the PTI-1 UTRs are
required for the transforming capacity of PTI-1 [8].
Since the mutation of the ORF1 start-codon does not
affect the oncogenic properties of full-length PTI-1
mRNA negatively, a more truncated version of eEF1A1
must also be oncogenic. Additional experiments are re-
quired to pinpoint, which eEF1A1 truncations are re-
sponsible for eliciting the transformed phenotype.
Figure 5 Foci formation at 5% serum. NIH 3 T3 cells were stably transfected with the indicated constructs. Three sets of cell lines were
independently established and analyzed for each construct. (A) shows the number of foci counted in the various cell lines, while (B) and (C)
depict representative examples of background growth and foci growth, respectively. In A, standard deviations are shown. The construct expressing the
full-length PTI-1 mRNA with a mutation in the start codon of ORF1 is clearly transforming (a comparison of the number of foci obtained for the
pZeoSV2-PTI-1-FL-ΔATG and empty pZeoSV2 in a Student's t-test results in a P value of 0.024).
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Cellular localization of the PTI-1 protein
In eukaryotic cells, a large proportion of specific mRNA
species exhibit a distinct localization within the cell as a
mechanism of providing for localized synthesis of the
encoded protein close to its site of action [16]. The PTI-1
proteins expressed from the UTR-containing constructs
displayed a predominant nuclear localization, while the
mRNA containing only ORF1 gave rise to a protein, which
was primarily located in the cytoplasm (Figure 6).
The fact that the pattern of subcellular localization
was independent of the amino acid sequence of PTI-1
rules out a post-translational mechanism of localization
based on e.g. the presence of a nuclear localization signal.
A more plausible explanation could be that the mRNA is
localized to the perinuclear area and that subsequent
translation of the protein close to the nucleus facilitates
its nuclear import. The nuclear localization of a number
of proteins including among others c-fos, c-myc and
metallothionein-1 (MT-1) appear to be depending on zip-
codes in the 3′UTRs of mRNAs, which are consequently
anchored in the perinuclear region via interactions with
trans-acting factors [17-19]. Upon translation, the im-
mediate vicinity of its final destination facilitates nuclear
import of the resulting protein.
A similar scenario of perinuclear mRNA anchoring fol-
lowed by protein import to the nucleus can be envisaged
for PTI-1. The majority of known zipcodes are found in
the 3′UTR, but examples of a 5′UTR localization exist as
Figure 6 Intracellular localization of PTI-1 protein. V5-tagged PTI-1 protein was transiently expressed in NIH 3 T3 cells from the constructs
pcDNA3.1-PTI-1-ORF1, pcDNA3.1-PTI-FL and pcDNA3.1-PTI-1-FL-ΔATG. The cells were fixed and stained with mouse anti-V5 antibody and Alexa-fluor®
488 goat anti-mouse antibody (green) and the DNA stain TO-PRO-3 (red). (A) Images recorded by CLSM using a x100 oil-immersion objective showing
the localization of V5-tagged PTI-1 protein and nuclear DNA. (B) Scoring of the cellular distribution of PTI-1 protein. The transiently transfected cells
were observed under a fluorescent microscope. The assay was repeated three times with three independent transfections with each construct. Over
100 cells were scored each time for each construct transfection. The cells were assigned to one of three categories: mainly nuclear localization
(red bars), mainly cytoplasmatic localization (green bars) or even distribution between the nucleus and the cytoplasm (yellow bars). Standard
deviations are shown.
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well e.g. in the Drosophila gurken mRNA [20]. Either of
these possible localizations of zip codes remains open
in the case of PTI-1. The 3′UTR is shared between
PTI-1 and eEF1A1 mRNA, while the 5′UTR is unique
to PTI-1 and could therefore be held responsible for
the nuclear targeting of PTI-1 products. In contrast,
the presence of an independently functioning zip code
in the ORF regions as observed in the yeast Ash1 tran-
script [21] can be excluded.
Oncogenic effects of the PTI-1 protein in the nucleus
The results obtained in this study indicate that the nuclear
localization of proteins expressed from UTR-containing
PTI-1 transcripts is a prerequisite for them to exert their
oncogenic properties. How does the nuclear presence of
one or more eEF1A1 truncations cause transformation?
eEF1A is generally considered a cytoplasmatic protein
[22,23] in accordance with its primary role in translation.
A number of studies, however, report the nuclear pres-
ence of eEF1A in relation to e.g. apoptosis [24], cell pro-
liferation [25] and cancer [26]. It is tempting to suggest
that the abnormal presence of truncated forms of eEF1A
in the nucleus may interfere with different nuclear func-
tions of eEF1A thereby leading to dysregulation of these
with the potential of causing cancer. The most relevant,
potential roles of eEF1A1 in the nucleus that could be
affected by the company of PTI-1 are described in the
following.
The nuclear presence of eEF1A may be a normal fea-
ture of proliferating cells. It has been observed that
eEF1A is recruited to the nucleus upon mitogen stimula-
tion and assist the zinc finger protein ZPR1 in driving
cell cycle progression [25,27]. The promiscuous presence
of PTI-1 in the nucleus could potentially invoke a misre-
gulation of this pathway leading to mitogen-independent
proliferation.
eEF1A1 and −2 have both been reported to interact
with sphingosine kinases 1 and 2 (SK1, SK2) and cause
their activation [28,29]. The canonical role of SK1 is to
catalyse the formation of sphingosine-1-phosphate (S1P)
from a sphingolipid precursor. In contrast to the precur-
sor, S1P promotes cellular division and inhibit apoptosis.
While SK1 appears to be primarily cytosolic, SK2 shut-
tles between the nucleus and the cytoplasm, [30]. SK2
has been shown to play a distinct role from SK1 and to
inhibit growth and induce apoptosis [31,32,33]. The nu-
clear function of SK2 is unknown and might involve S1P
independent pathways.
Akt is a threonine/serine kinase that regulates the ac-
tivities of numerous targets related to cell survival and
proliferation. Akt itself is activated via phosphorylation
by phosphoinositide-dependent protein kinase 1 (PDK1).
Phosphorylation of Akt facilitates its nuclear translo-
cation and retention [34]. Yet, the role of pAkt in the
nucleus is not clear and may be related to its well-
known pro-proliferative/anti-apoptotic function or to
newly discovered pro-apoptotic pathways [35,36]. eEF1A
has been found to interact with pAkt [37,38]. Thus, PTI-
1 could potentially interact with nuclear pAkt and inter-
fere with its signaling activities.
Conclusions
The PTI-1 oncogene potentially encodes a number of
shortened variants of translation elongation factor eEF1A1.
We found that the untranslated regions (UTRs), which
are essential for transformation, do not influence on
protein expression, but plays a critical role during nu-
clear localization of the encoded oncoprotein product(s),
which may be shorter than previously predicted. Several
eEF1A interaction partners are found in the nucleus,
where they regulate cell proliferation and survival. The
nuclear localization of eEF1A truncations encoded by
the PTI-1 transcript may interfere with the pathways
of the eEF1A interaction partners possibly provoking




The PTI-1 DNA was previously obtained from Dr. Fisher,
Columbia University, New York and sequenced upon re-
ceipt [3]. The donated fragment is identical to the ~ 1.9 kb
oncogenic fragment described by Su et al. [4] and will
be referred to as full-length PTI-1 throughout the paper.
For site-directed mutagenesis, the QuickChange® II Site-
Directed Mutagenesis Kit (Stratagene) was employed.
The constructs pZeoSV2-PTI-1-ORF1, pZeoSV2-PTI-
1-FL and pZeoSV2-PTI-1-FL-ΔATG were employed in
oncogenicity assays as described below. The pZeoSV2
vector (Invitrogen) was chosen for these experiments,
since the same vector had previously been used to demon-
strate the oncogenicity of PTI-1 [8]. Furthermore, these
vectors were applied for in vitro analysis of protein
expression profiles (see below). The full-length PTI-1
gene and the ORF1 of the PTI-1 gene were cloned into
pZeoSV2 resulting in the constructs pZeoSV2-PTI-1-FL
and pZeoSV2-PTI-1-ORF1 respectively. The construct
pZeoSV2-PTI-1-FL-ΔATG was created by site-directed
mutagenesis of pZeoSV2-PTI-1-FL exchanging the T in
start codon initiating ORF1 for a C.
The constructs pcDNA3.1-PTI-1-FL-V5, pcDNA3.1-PTI-
1-ORF1-V5 and pcDNA3.1-PTI-1-FL-ΔATG-V5 were
employed for the analysis of protein expression profiles
in vivo. The PTI-FL and PTI-1-ORF1 inserts were sub-
cloned from their respective pZeoSV2 constructs into
the pcDNA3.1 vector. Next, a sequence encoding a
C-terminal V5-tag was inserted in-frame by site-directed
mutagenesis thereby creating pcDNA3.1-PTI-1-FL-V5 and
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pcDNA3.1-PTI-1-ORF1-V5. The construct pcDNA3.1-
PTI-1-FL-ΔATG-V5 was generated by mutating the start
codon of the pcDNA3.1-PTI-1-FL-V5 vector in a manner
identical to the one described for mutagenesis of the start-
codon in pZeoSV2-PTI-1-FL.
For all constructs, the correctness of the insertions
and the integrity of the constructs were confirmed by
sequencing. In addition, the correctness of promotor se-
quences and polyadenylation sites were confirmed.
Protein expression analysis
Protein expression analysis in vitro was performed using
the transcription/translation assay kit, Proteinscript® II T7
kit from Ambion. [35S]-methionine was purchased from
Perkin Elmer. Transcription reactions were carried out as
recommended by the manufacturer. DNA templates were
the linearized pZeoSV2-PTI-1-FL and the positive control
pTRI-Xef included in the kit. 0.5 μg DNA was used in
each reaction. A negative control reaction without DNA
was included. The transcription reactions were used as
templates in the translation reactions. The positive control
reaction was mixed as prescribed by the protocol contain-
ing a final methionine concentration of 30 μM of which
0.5 μM were [35S]-methionine (1100 Ci/mmol). For the
other two reactions, the final methionine concentration
was 25 μM of which 1 μM was [35S]-methionine (1100 Ci/
mmol). 15-μl portions of each of the translation reactions
were loaded and run on a 12% SDS polyacrylamide gel or
a precast 12% BIS TRIS gel (Bio-Rad). The gel was dried
in a gel dryer. An X-ray film (Konica Minolta) was ex-
posed to the dried gel for 2 days.
The in vivo protein expression profile of the PTI-1 gene
was accessed using the constructs pcDNA3.1-PTI-1-FL-
V5, pcDNA3.1-PTI-1-FL-ΔATG-V5, and pcDNA3.1-PTI-
1-ORF1-V5. Transient transfection was performed as
described for the establishment of stable cell lines (see
below) with the exception that circular DNA was employed.
Six hours after transfection, the medium was changed.
The cells were incubated for approximately 48 hours
before they were harvested for analysis. A transfection
with pZeoSV2/lacZ was always included as a transfection
control. A negative control was transfected with an empty
pcDNA3.1 vector. The harvested cells were washed in
PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4,
2 mM KH2PO4), resuspended in 100 μl lysis buffer
(150 mM NaCl, 10 mM MgCl2, 1 mM DTT, 10% glycerol,
0,5% NP-40, 50 mM Tris/HCl pH 7.5 and complete
EDTA-free inhibitor (Roche)), and incubated for one hour
on ice. The protein concentration of the lysate was deter-
mined using the Bradford assay [39]. The protein samples
were run on a 10% SDS polyacrylamide gel and subjected
to Western blotting. V5-tagged PTI-1 was detected with a
HRP-conjugated rabbit anti-V5 tag polyclonal antibody
(Genscript) used in a concentration of 0.5 μg/ml. The blot
was developed with the ECL Plus Western blotting detec-
tion system (GE Healthcare) and visualized on X-ray film
(Konica Minolta).
Cell culture
NIH 3 T3 cells were purchased from the American Type
Culture Collection and their alleged contact inhibited
growth was confirmed in a foci-formation assay. The
number of colonies arising after transfection of a 36-mm
well was estimated in an experiment where selection
was performed on a very large growth area omitting the
need for splitting the cells during selection.
Cells were grown in DMEM (DMEM+GlutaMAX™-I
from GIBCO) containing 10% bovine calf serum (SAFC
Biosciences), 100 units penicillin/ml, and 100 μg strepto-
mycin/ml. The cells were split regularly to keep them
below 80% confluency at all times.
Establishment of stable cell lines
The pZeoSV2 constructs were linearized with BspHI
and purified by phenol-chloroform extraction. NIH 3 T3
cells were seeded in 36-mm wells, 400.000 cells per well.
The following day, the cells were transfected with 4 μg
DNA using Lipofectamine™ 2000 transfection reagent
(Invitrogen). The DNA used for transfection was diluted
in OPTI-MEM®I (GIBCO) and sterile filtered prior to
transfection. Duplicate or triplicate transfections were
made with each construct. A transient transfection with
pZeoSV2/lacZ was always included as a transfection
control. Six hours after transfection, the cells were
reseeded onto larger surfaces. Two days after transfec-
tion, zeocin (Invitrogen) was included in the medium at
0.5 mg/ml. This concentration was chosen based on kill
curves as described in the zeocin manual. Plasmocin
(Invivogen) was also included in the medium at a con-
centration of 5 μg/ml to prevent Mycoplasma infection.
The medium and antibiotics were changed every 3–4 days
during selection. The cells were reseeded regularly to
avoid incubation at confluency. The selection was consid-
ered finished when no more cells remained in the non-
transfected control flasks (after 24 days). At that point,
zeocin was no longer included in the growth medium
of the cells. In contrast, plasmocin was maintained in the
medium until the day of injection into mice (see below).
Stably transfected cell lines were tested free of Myco-
plasma by either Hoechst staining or by PCR using the
Mycosensor™ PCR Assay kit (Stratagene).
RT-PCR was applied to the stably transfected cell lines
to confirm the expression of integrated constructs as fol-
lows: mRNA was extracted from one million cells of
each stable cell line with the RNeasy® Mini Kit (Qiagen).
A DNase cleavage step was included employing RNase-
free DNase (Qiagen). The purified RNA was used as
a template in an RT-PCR reaction using the OneStep
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RT-PCR Kit (Qiagen). DNA contamination controls were
included in which the reverse transcription step was
omitted. The amplification of the PTI-1-ORF1 and empty
vector pZeoSV2 transcripts was performed with vector-
specific primers RTplasrev (5′-CTAGAAGGCACAGTC
GAGGCTG-3′) and RTplasfor (5′-TAGAGAACCCACT
GCTTACTGGC-3′). The transcripts from PTI-1-FL and
PTI-1-FL-ΔATG were amplified with a primer matching
the PTI-1 5′UTR, RT23Srev (5′-CAGCTAGATGCCGC
CATTCCAC-3′), combined with the vector-specific pri-
mer, RTplasfor.
Foci forming assays
The experiments were performed on stably transfected
NIH 3 T3 cells that had been propagated at subcon-
fluency for 12 days after ended zeocin selection. Then,
400,000 cells of each cell line were seeded subconflu-
ently in a T25 flask in medium containing 10% serum.
The following day, the medium was changed to 5%
serum and the cells were incubated for three weeks.
The medium was changed every 3–4 days. The cells
were fixed in icecold methanol and stained with Giemsa
stain (Giemsas Azur-Eosin Methylene blue solution
from Merck) and colonies were scored.
Tumorigenicity assay
The established stable cell lines were propagated. On the
day of injection, the cells were trypsinized (Trypsin
EDTA 170,000 U/l; Lonza), resuspended in medium and
counted in a Coulter counter. The cells were washed
once in Hank’s balanced salt solution (HBSS; Lonza),
resuspended in HBSS and kept on ice until the moment
of injection into NCr nude mice (Taconic Europe). Two
injections were made on each mouse, one on each flank.
Each injection contained 5 million cells. After the in-
jection, the remaining cells were seeded in flasks and
proven to be fully viable. Tumor development was followed
with a slide gauge using the formula: V = (π/6)×((l + w)/2)3
in which V = volume/cm3, l = length/cm, w =width/cm.
1 cm3 tumor is assumed to weigh 1 g. The mice were sacri-
ficed before the tumor reached a size of 1 cm3. The tumors
were excised and weighed.
Protein localization
NIH 3 T3 cells were transiently transfected with pcDNA3.1-
PTI-1-FL-V5, pcDNA3.1-PTI-1-ORF1-V5, pcDNA3.1-PTI-
1-FL-ΔATG-V5 and the empty pcDNA3.1 vector using
the Lipofectamine™ 2000 transfection reagent (Invitro-
gen). For each transfection, 0.2 μg of the relevant
construct was mixed with 3.8 μg of the empty vector.
The day after transfection, the cells were reseeded into
9 cm2 slideflasks with 200,000 cells per flask. The fol-
lowing day, the cells were fixed and stained as follows:
The slides that were used for cell counting were
incubated with Hoechst 33258 prior to fixation. The
cells were washed with Dulbecco's Phosphate Buffered
Saline (DPBS; Lonza) and fixed by incubation in neutral
buffered formalin (Lilly’s liquid; VWR) followed by fixation
in 70% ethanol at −18°C. The slides were washed in PBS
prior to a 1-hour incubation with anti-V5 antibody (Anti-
V5 Antibody mouse monoclonal IgG2a from Invitrogen)
diluted 1/100 in 50 μl blocking buffer (0.5% BSA, 15 mM
NaN3). The slides were washed in PBS and incubated for
1 hour with Alexa Fluor® 488 goat anti–mouse IgG anti-
body (Invitrogen) diluted to 5 μg/ml in 50 μl blocking buf-
fer. The slides were finally washed in PBS. The cells were
scored under a fluorescent microscope (Zeiss Axioplan
2 Imaging) using a × 63 objective and Zeiss filter set 10
(Excitation: 450–490 nm, Beam Splitter: 510 nm, Emission
515–565 nm) for visualization of Alexa 488 and Zeiss filter
set 34 (Excitation: 390/22 nm, Beam Splitter: 420 nm,
Emission: 460/50 nm) for visualization of Hoescht 33258.
The slides to be analyzed by confocal laser scanning mi-
croscopy (CLSM) were added 1 μM TO-PRO-3 (Molecular
Probes, Invitrogen) in PBS for 5 minutes to stain the DNA
and washed twice in PBS as previously described [40]. The
slides were added anti-fade mounting medium (VECTA-
SHIELD® Mounting Medium from VECTOR laboratories)
and sealed. The cells were analyzed by CLSM (TCS SL,
Leica) using a ×100 oil-immersion objective with a numer-
ical aperture of 1.4. Imaging was performed by using a
488 nm line of a multiline argon laser (detection of Alexa-
488) and the 633 nm line of a helium-neon laser (detection
of TO-PRO-3).
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